This real-world US evidence demonstrates the potential of AI-enabled imaging biomarkers to help identify missed and incidental lung nodules earlier within routine chest radiograph workflows. The findings highlight the ability of AI to surface high-risk cases, including aggressive subtypes such as small cell lung cancer (SCLC), at a stage where timely intervention would still be possible. Discover how AI-driven detection could support earlier diagnosis, faster care pathway activation, and improved patient engagement opportunities.
